Clinical Trial

[18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease

Recruiting
View on ClinicalTrials.gov →
Summary
To investigate the primary brain regions of precursors of Alzheimer's disease and Alzheimer's disease by novel molecular probe \[18F\]AV45(Aβ) and \[18F\]AV1451(Tau)PET/CT imaging. And the distribution of positive lesions in the brain area affecting the simple mental state examination and the Montreal Cognitive Assessment Scale in AD patients; It is expected to provide molecular imaging information for further study of the pathogenesis of AD. After clinical transformation, objective and quantitative positive diagnostic criteria for \[18F\]AV45 and \[18F\]AV1451PET/CT in the diagnosis of early Alzheimer's disease were established to avoid the defects of relying on the subjective experience of doctors and time-consuming diagnosis.
Trial Details
NCT Number NCT06833645
Lead Sponsor Sichuan Provincial People's Hospital
Conditions Alzheimer's Disease
Enrollment 280 participants
Start Date 2024-05-10
Primary Completion 2025-02-19 (estimated)
Study Completion 2025-02-25 (estimated)
Updated on ClinicalTrials.gov 2025-02-19